non-radiographic axial spondyloarthritis
Rheumatology · 2015–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bimekizumab Treatment of adult patients with non-radiographic axial spondyloarthritis (nr-axSpA) who have failed to achieve an adequate response to at least 2 nonsteroidal… | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia |
| ixekizumab Treatment of adult patients with active non-radiographic ankylosing spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated… | Jul 2023 | Recommended with restriction | none received |
| upadacitinib Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in adults with active disease who have inadequate response to NSAIDs. | Mar 2023 | Deferred | none received |
| secukinumab Amendment request to increase maximum quantity from one to two injections and reduce repeats from five to two for continuing treatment of ankylosing… | Jul 2021 | Not recommended | none received |
| ixekizumab Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation as indicated by elevated CRP and/or MRI… | Nov 2021 | Recommended with restriction | none received |
| secukinumab Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation (elevated C-reactive protein and/or MRI… | Nov 2020 | Recommended with restriction | none received |
| certolizumab pegol Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation (elevated CRP and MRI evidence) who have had… | Nov 2019 | Recommended with restriction | none received |
| golimumab Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation (elevated CRP and/or MRI evidence) who have… | Jul 2018 | Recommended with restriction | 4 individuals CreakyJoints Australia |
| golimumab Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation (elevated CRP and/or MRI evidence) who have… | Nov 2017 | Not recommended | 2 individuals Translational Research Institute |
| etanercept Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in adults with active disease (BASDAI ≥4) who have had an inadequate response to at least two… | Mar 2016 | Not recommended | none received |
| etanercept Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in adults with active disease, characterized by chronic back pain for ≥3 months and onset… | Mar 2015 | Not recommended | none received |
Who spoke
CreakyJoints Australia · Translational Research Institute
What the PBS pays
$772M in government benefit over 2024–25, across 559,094 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| upadacitinib | $291.6M |
| secukinumab | $120.2M |
| golimumab | $97.7M |
| etanercept | $79.8M |
| ixekizumab | $70M |
| certolizumab pegol | $57.5M |
| bimekizumab | $54.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 5 technologies for this condition, recommending 5 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| bimekizumabBimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA918 | recommended restricted | 2023-10 |
| upadacitinibUpadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | recommended restricted | 2023-02 |
| ixekizumabIxekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA718 | recommended restricted | 2021-07 |
| golimumabGolimumab for treating active non-radiographic axial spondyloarthritis | TA497 | recommended | 2018-01 |
| tnf alpha inhibitorsTNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | recommended | 2016-02 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.